Peptides Codex
ENFR
← Home
Research peptide

CJC-1295

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) studied for effects on the GH/IGF-1 axis. Variants with and without DAC (Drug Affinity Complex) appear in research discussions.

By The Peptides Codex Editorial TeamReviewed July 10, 2026
Length
30 aa
Class
Research peptide
Function
GHRH analog studied for GH axis effects
Context
Research compound (not an approved drug)

Growth-hormone secretagogue research is a high-volume peptide search cluster.

Also known as: CJC1295 · DAC:GRF

Part of the Growth hormone & IGF peptides cluster

Overview

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) studied for effects on the GH/IGF-1 axis. Variants with and without DAC (Drug Affinity Complex) appear in research discussions.

Source & context

Biological / chemical source: Synthetic GHRH analog

Primary research or clinical context: Research compound (not an approved drug)

With vs. without DAC

DAC-containing versions were designed to extend circulating half-life via albumin binding. Research discussions often distinguish CJC-1295 with DAC from modified GRF 1-29 (sometimes called CJC-1295 without DAC).

Stacking context (educational)

Online research communities frequently discuss CJC-1295 alongside GHRP-family peptides such as ipamorelin. This site covers mechanisms and nomenclature only — not protocols or human use guidance.

FAQ about CJC-1295

What is CJC-1295?+

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) studied for effects on the GH/IGF-1 axis. Variants with and without DAC (Drug Affinity Complex) appear in research discussions.

Is CJC-1295 an approved medicine?+

CJC-1295 is discussed here as a research / educational topic. Research compound (not an approved drug). This is not medical advice.

What is the typical length of CJC-1295?+

CJC-1295 is commonly described as approximately 30 amino acids (Research peptide).

Related peptides

GLP-1
Incretin
GLP-1 (glucagon-like peptide-1) is an incretin hormone that stimulates insulin secretion and influences appetite. Engineered analogs dominate modern metabolic medicine research.
Semaglutide
Incretin analog
Semaglutide is a modified GLP-1 receptor agonist peptide designed for extended half-life. It is an approved prescription medicine in many jurisdictions and a major case study in peptide engineering.
BPC-157
Research peptide
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide studied in preclinical models of tissue repair and gastrointestinal protection. It is not an approved therapeutic in Canada or the United States.
TB-500
Research peptide
TB-500 refers to a synthetic peptide fragment associated with thymosin beta-4 research, studied for effects on cell migration and tissue remodeling in experimental models. It is not an approved medicine.

References & further reading

  1. 1.Wikipedia — CJC-1295
  2. 2.PubChem — compound summary for CJC-1295 (CID 91971820)
  3. 3.Teichman et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab
  4. 4.Ionescu et al. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab
  5. 5.Jetté et al. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology
  6. 6.Sackmann-Sala et al. (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res
  7. 7.Stanley et al. (2011). Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab
  8. 8.Falutz et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med
  9. 9.Falutz et al. (2010). Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr
  10. 10.Halmos et al. (2023). Signaling mechanism of growth hormone-releasing hormone receptor. Vitam Horm
  11. 11.Baker et al. (2012). Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol
  12. 12.Friedman et al. (2013). Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA Neurol
  13. 13.Vittone et al. (1997). Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism
  14. 14.Merriam et al. (2003). Growth hormone-releasing hormone and growth hormone secretagogues in normal aging. Endocrine
  15. 15.Memdouh et al. (2021). Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal
Disclaimer: Educational content only. Not medical advice. Not instructions for human use. Research peptides and unapproved products may be restricted or illegal to market for human consumption in your jurisdiction. Consult qualified professionals and applicable law.
You might also like: All peptides · Atlas · Research · Tools
Cite this: Peptides Codex — CJC-1295 educational profile.
Tip: Use browser print (Ctrl/Cmd + P) for a clean PDF of this page.